STEP 1
Consultation and Metabolic Review
We review your medical history, prior weight loss efforts, symptoms, goals, and current medications to determine whether semaglutide is appropriate.
Our semaglutide weight loss program is designed for patients who want a medically guided approach to appetite control, portion reduction, and sustainable fat loss. Treatment is personalized, monitored over time, and supported by provider oversight plus life coach access for every active patient.
For many patients, weight gain is not simply about motivation or discipline. It is often driven by persistent hunger, cravings, poor satiety, insulin resistance, slowed metabolic function, stress eating, and hormone-related changes. Even motivated people can feel like they are fighting their own biology.
Semaglutide may help support a more manageable path toward calorie reduction by improving appetite regulation and helping patients feel satisfied with less food.
Supported in All 50 States.
Semaglutide is a GLP-1–based medication used to support appetite regulation and satiety. For appropriate patients, it may help reduce hunger, slow gastric emptying, and support more consistent nutritional adherence over time.
At TruLife Metabolix MD, treatment is not built around medication alone. Your care plan is designed around medical evaluation, dose titration, follow-up, and behavioral support.
We review your medical history, prior weight loss efforts, symptoms, goals, and current medications to determine whether semaglutide is appropriate.
If appropriate, we create a semaglutide plan based on your starting point, tolerability, and metabolic goals.
Your progress is followed over time so the dose can be advanced carefully and adjusted for response and side effects.
All active patients have access to life coach support for accountability, adherence, meal consistency, and habit change.
Our semaglutide program is offered primarily as a once-weekly injectable treatment, which is the most common format for medical weight loss. There is also an oral semaglutide option that may be discussed for patients who prefer a non-injectable route, depending on clinical fit and availability. Current Wegovy labeling includes both injection and tablet formulations.
Supported in All 50 States.
Semaglutide is usually started low and increased gradually to improve tolerability, especially for gastrointestinal side effects.
A common weekly injectable progression is:
–0.25 mg once weekly for the first 4 weeks
–0.5 mg once weekly for weeks 5 to 8
–1 mg once weekly for weeks 9 to 12
–1.7 mg once weekly for weeks 13 to 16 then advancement to a usual maintenance level such as 2.4 mg once weekly.
If appropriate and well tolerated For patients interested in the oral formulation, the branded weight-loss tablet version is titrated separately and starts at 1.5 mg once daily, with increases every 30 days as tolerated up to 25 mg once daily.
The most common side effects with semaglutide are usually gastrointestinal, especially during the first several weeks or after a dose increase.
These may include:
These side effects are often most noticeable during initiation and titration, which is why the medication is typically advanced in stages rather than started at a full dose.
At TruLife Metabolix MD, we work to improve tolerability by:
Many patients find that early GI symptoms improve as their body adjusts over the first few weeks, especially when dose escalation is handled carefully. The staged dosing schedule is specifically used to reduce gastrointestinal adverse effects.
Supported in All 50 States.
If you are already taking semaglutide through another provider, you may be able to continue at your current dose rather than restart from the beginning.
During your initial consultation, we review your recent treatment history and may validate your current prescription before deciding whether continuation at your present dose is appropriate. This helps stable patients maintain momentum during a provider transition.
Supported in All 50 States.
If you have missed semaglutide for an extended period, the next step depends on how long you have been off treatment and how well you previously tolerated it.
Supported in All 50 States.
FDA labeling for injectable Wegovy states that if 2 or more consecutive doses are missed, patients may either resume as scheduled or, if needed, reinitiate the escalation schedule to reduce GI side effects associated with restarting.
If you have been off semaglutide for more than 4 weeks, your dose may need to be reassessed and often restarted at or near a lower level to reduce the chance of nausea and stomach-related side effects. The exact restart plan depends on your prior dose, your tolerance history, and how long treatment has been interrupted.
Semaglutide-based treatment may help support:
At TruLife Metabolix MD, we aim to provide innovative telemedicine solutions for metabolic weight loss and hormone optimization.
This is the starting monthly price for patients who prefer flexibility. We also offer discounted package pricing on longer plans.
Your program is built around more than a prescription.
Many programs simply prescribe and disappear. Our model is designed to help patients stay supported and engaged throughout treatment.
We’ve compiled answers to the most common questions our clients ask to help you get a better understanding of how we can assist you.
For the weekly injectable program, the common starting dose is 0.25 mg once weekly, then it is increased gradually over time as tolerated.
Most patients use semaglutide as a once-weekly injection, though an oral weight-loss tablet option is also available in some cases.
Dose escalation is used to reduce common GI side effects such as nausea, bloating, constipation, diarrhea, and vomiting.
Often, yes. If you are already taking semaglutide and can provide a valid current prescription that can be reviewed during your consultation, continuation at your current dose may be possible.
Your treatment will usually need to be reassessed. Depending on how long you have been off and how well you previously tolerated it, you may need to restart at or near a lower dose to reduce GI side effects. FDA labeling states that after 2 or more consecutive missed injectable doses, reinitiating the escalation schedule may be appropriate.
Usually, yes. Many patients notice that nausea and other GI effects are most pronounced early in treatment or after dose increases and often improve over the first few weeks as the body adjusts.
Yes. Qualified patients may complete consultation, treatment planning, and follow-up through telehealth.
Take control of hunger with a medical weight loss plan built for real life. Start with flexible month-to-month semaglutide treatment, or save more with 3-month and 6-month options.
